A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. [electronic resource]
Producer: 20150918Description: 138-47 p. digitalISSN:- 1573-0646
- Adult
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Camptothecin -- administration & dosage
- Cetuximab
- Colorectal Neoplasms -- drug therapy
- Drug Resistance, Neoplasm
- Female
- Humans
- Indazoles
- Irinotecan
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neutropenia -- chemically induced
- Protein Kinase Inhibitors -- administration & dosage
- Pyrimidines -- administration & dosage
- Recurrence
- Sulfonamides -- administration & dosage
- Topoisomerase I Inhibitors -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.